The rapidly changing landscape of RSV protection It took many decades for RSV vaccines to arrive in general practices. But why did it take so long and what impact are they having now?
‘We cannot separate environmental health from human health’ On World Environment Day, one GP is reminding colleagues of ways to reduce their impacts, starting with ‘action on low-hanging fruit’.
TGA warns of ‘possible but rare’ RSV vaccines risk Product Information for Arexvy and Abrysvo has been updated to reflect a low risk of Guillain-Barre Syndrome following vaccination.
Why doesn’t Australia make more medicines? Medicine shortages in Australia are not new. So, could we prevent medication shortages if Australia made more medicines?
‘The same challenges’: Lessons from remote Canada They may be half a world apart but country doctors in Canada and Australia have a lot they can teach each other, finds the RACGP’s Rural Chair.
In Practice: Changes to dual-labelled medicine ingredient names The TGA has advised that more dual-labelled medicine ingredient names have begun the transition to sole ingredient names.
RSV vaccine approved for use in at-risk over-50s The new TGA approval allows access to the Arexvy vaccine for at-risk adults aged 50–59, expanding the previous indication.
Longer pollen season bringing more risk for asthma patients Research shows the hay fever season is growing longer, and one expert says GPs are at the forefront of helping patients reduce complications.
Study examines whether RSV vaccine lasts ‘at least three winters’ The results of a randomised controlled trial indicate an RSV vaccine could offer protection against the virus over three seasons in over 60s.
General practice pilot to ease ‘significant impacts’ of hay fever To boost low adherence to treatments, a new trial aims to support GPs through a tailored education toolkit used alongside daily nasal spray.